Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is well-positioned for long-term growth and profitability as it continues to expand its comprehensive molecular information solutions and AI/ML technology in the healthcare industry. Its strong cash flow generation and financial stability, coupled with its partnerships with key biopharma companies and growing payer coverage, indicate a solid financial foundation. The recent data published by Caris on the effectiveness of its Caris Assure platform and its plans for continued expansion in early detection and MRD tracking further support the company's positive outlook and potential for significant operating leverage in the future. Despite potential challenges or risks related to competition and regulatory compliance, Caris' innovative approach and track record of success make it an attractive investment opportunity.

Bears say

Caris Life Sciences is a company in the precision medicine industry that has experienced strong growth, but it now faces increased competition and market saturation. Additionally, the company's revenue may be partially inflated due to true-ups in its financial reporting. Caris' success relies on its ability to keep up with advancing technology and evolving industry standards, and any failure to do so could negatively impact its business.

CAI (CAI) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 11 analysts, CAI (CAI) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.